• Publications
  • Influence
Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection?
BackgroundPancreas is a possible site of metastases from renal cell carcinoma (RCC). The aim of this study was to define the role of surgery in their treatment.MethodsWe retrospectively analyzed 36Expand
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
The aim of this study was to evaluate the safety profile of s.c. administered recombinant human interleukin 12 (rHuIL-12). Pharmacokinetics and pharmacodynamics of rHuIL-12 and any evidence ofExpand
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
BACKGROUND NGR-hTNF consists of human tumour necrosis factor-alpha (hTNF-alpha) fused to the tumour-homing peptide NGR, a ligand of an aminopeptidase N/CD13 isoform, which is overexpressed onExpand
Nephroprotective Effect of Bosentan in Diabetic Rats
Previous studies have suggested that endothelins could be involved in the pathogenesis of target organ damage in diabetes. The aim of this study was to evaluate the possible protective effect ofExpand
Solitary psoas muscle metastasis from renal cell carcinoma
We report a case of a very unusual presentation of a colonic carcinoma. Seven years after ileal conduit urinary diversion, a 50-yearold patient was referred to us with the symptoms of extremeExpand
Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Systemic effects on T-cell-mediated antitumor immunity, on expression of T-cell adhesion/homing receptors, and on the promotion of T-cell infiltration of neoplastic tissue may represent key steps forExpand
Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer.
BACKGROUND--Immunotherapy with recombinant interleukin 2 (rIL 2) has been extensively used to treat cancer but its use has been hampered by serious side effects including severe hypotension,Expand
Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
Starting from in vitro studies suggesting synergistic antitumour activity against renal cell cancer (RCC) of recombinant interleukin-2 (rIL-2) and alpha-interferon (IFN), a phase II trial wasExpand
Plasmapheresis in the treatment of stiff-man syndrome.